Izmir Biomedicine and Genome Center, 35340 Izmir, Turkey; Department of Medical Biology and Genetics, Health Science Institute, Dokuz Eylul University, 35340 Izmir, Turkey.
Faculty of Medicine, Koç University, 34450 Istanbul, Turkey.
Stem Cell Reports. 2019 Oct 8;13(4):627-641. doi: 10.1016/j.stemcr.2019.08.007. Epub 2019 Sep 12.
Organoid technologies have become a powerful emerging tool to model liver diseases, for drug screening, and for personalized treatments. These applications are, however, limited in their capacity to generate functional hepatocytes in a reproducible and efficient manner. Here, we generated and characterized the hepatic organoid (eHEPO) culture system using human induced pluripotent stem cell (iPSC)-derived EpCAM-positive endodermal cells as an intermediate. eHEPOs can be produced within 2 weeks and expanded long term (>16 months) without any loss of differentiation capacity to mature hepatocytes. Starting from patient-specific iPSCs, we modeled citrullinemia type 1, a urea cycle disorder caused by mutations in the argininosuccinate synthetase (ASS1) enzyme. The disease-related ammonia accumulation phenotype in eHEPOs could be reversed by the overexpression of the wild-type ASS1 gene, which also indicated that this model is amenable to genetic manipulation. Thus, eHEPOs are excellent unlimited cell sources to generate functional hepatic organoids in a fast and efficient manner.
类器官技术已成为一种强大的新兴工具,可用于模拟肝脏疾病、药物筛选和个性化治疗。然而,这些应用在以可重复且高效的方式生成功能性肝细胞方面受到限制。在这里,我们使用人诱导多能干细胞(iPSC)衍生的 EpCAM 阳性内胚层细胞作为中间产物,生成并表征了肝类器官(eHEPO)培养系统。eHEPO 可在 2 周内产生,并可长期(>16 个月)扩增,而不会失去向成熟肝细胞分化的能力。从患者特异性 iPSC 开始,我们模拟了瓜氨酸血症 1 型,这是一种由于精氨琥珀酸合成酶(ASS1)酶突变引起的尿素循环障碍。eHEPO 中与疾病相关的氨积累表型可以通过过表达野生型 ASS1 基因来逆转,这也表明该模型适合遗传操作。因此,eHEPO 是一种极好的无限细胞来源,可以快速有效地生成功能性肝类器官。